Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Generative AI is infiltrating everything you do online, including how you find information. If you're bored with traditional search, check out the top AI search engines we've tried. I’ve been writing ...

Are you worried about online privacy? Not a fan of anticompetitive practices? Maybe you just want a new take on web search? These 12 search engines beat Google in many ways. I've been testing PC and ...

Are you worried about online privacy? Not a fan of anticompetitive practices? Maybe you just want a new take on web search? These 12 search engines beat Google in many ways. Our team tests, rates, and ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Learn how to connect search, AI, and PPC into one unstoppable strategy. In a world ruled by algorithms, SEJ brings timely, relevant information for SEOs, marketers, and entrepreneurs to optimize and ...